Skip to main content

OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.

Publication ,  Journal Article
van Haaften-Day, C; Shen, Y; Xu, F; Yu, Y; Berchuck, A; Havrilesky, LJ; de Bruijn, HW; van der Zee, AG; Bast, RC; Hacker, NF
Published in: Cancer
December 1, 2001

BACKGROUND: Ovarian carcinoma remains the leading cause of death from gynecologic malignancy in Australia, the Netherlands, and the United States. CA-125-II, the most widely used serum marker, has limited sensitivity and specificity for detecting small-volume, early-stage disease. Therefore, a panel of three serum tumor markers-OVX1, CA-125-II, and macrophage-colony stimulating factor (M-CSF)-has been used to evaluate the sensitivity and specificity of multiple markers for the detection of early-stage ovarian carcinoma. METHODS: Preoperative serum levels of OVX1, CA-125-II, and M-CSF were measured in 281 patients with primary ovarian epithelial tumors of different histotypes. Among these tumors, 175 were malignant, 29 were of borderline malignancy, and 77 were benign. The three markers also were measured in sera from 117 apparently healthy women. Marker levels were considered abnormal at CA-125-II > 35 U/mL, OVX1 > 7.2 U/mL, and M-CSF > 3.5 ng/mL. RESULTS: Among 175 women with malignant ovarian tumors, at least one of the three serum markers was elevated in 85%, whereas CA-125-II was elevated in 80% (P = 0.008). In 58 patients with Stage I ovarian carcinoma, at least one of the three serum markers was elevated in 76%, whereas CA-125 levels were elevated in 66% (P = 0.04). For patients with borderline and benign tumors, a combination of the three antigens had slightly higher sensitivity compared with CA-125-II, but the differences were not statistically significant. Among 117 apparently healthy women, CA-125-II was elevated in 4%, and one of the three markers was positive in 17%. CONCLUSIONS: The sensitivity of a combination of three serum markers was significantly greater than the sensitivity of the CA-125-II assay alone in patients with primary ovarian epithelial tumors of different histotypes. This was true for all stages, including early-stage, potentially curable disease. When used as single markers, however, only the CA-125-II assay could distinguish invasive Stage I tumors from apparently healthy women.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer

DOI

ISSN

0008-543X

Publication Date

December 1, 2001

Volume

92

Issue

11

Start / End Page

2837 / 2844

Location

United States

Related Subject Headings

  • Sensitivity and Specificity
  • Regression Analysis
  • Proteins
  • Prognosis
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasms, Glandular and Epithelial
  • Neoplasm Invasiveness
  • Macrophage Colony-Stimulating Factor
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
van Haaften-Day, C., Shen, Y., Xu, F., Yu, Y., Berchuck, A., Havrilesky, L. J., … Hacker, N. F. (2001). OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer, 92(11), 2837–2844. https://doi.org/10.1002/1097-0142(20011201)92:11<2837::aid-cncr10093>3.0.co;2-5
Haaften-Day, C. van, Y. Shen, F. Xu, Y. Yu, A. Berchuck, L. J. Havrilesky, H. W. de Bruijn, A. G. van der Zee, R. C. Bast, and N. F. Hacker. “OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.Cancer 92, no. 11 (December 1, 2001): 2837–44. https://doi.org/10.1002/1097-0142(20011201)92:11<2837::aid-cncr10093>3.0.co;2-5.
van Haaften-Day C, Shen Y, Xu F, Yu Y, Berchuck A, Havrilesky LJ, et al. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer. 2001 Dec 1;92(11):2837–44.
van Haaften-Day, C., et al. “OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.Cancer, vol. 92, no. 11, Dec. 2001, pp. 2837–44. Pubmed, doi:10.1002/1097-0142(20011201)92:11<2837::aid-cncr10093>3.0.co;2-5.
van Haaften-Day C, Shen Y, Xu F, Yu Y, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Bast RC, Hacker NF. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer. 2001 Dec 1;92(11):2837–2844.

Published In

Cancer

DOI

ISSN

0008-543X

Publication Date

December 1, 2001

Volume

92

Issue

11

Start / End Page

2837 / 2844

Location

United States

Related Subject Headings

  • Sensitivity and Specificity
  • Regression Analysis
  • Proteins
  • Prognosis
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasms, Glandular and Epithelial
  • Neoplasm Invasiveness
  • Macrophage Colony-Stimulating Factor
  • Humans